Long Ideas - AbbVie (NYSE:ABBV), the R&D-focused spinoff of Abbot Laboratories (NYSE:ABT), began its first day of trading on the NYSE on Wednesday, and we expect shares of … Continue Reading
Read NowLong Ideas - Shares of BioMarin Pharmaceuticals (NASDAQ:BMRN) have risen roughly 40% in 2012, driven by solid Phase III data for BMRN’s lead investigational product GALNS, a treatment … Continue Reading
Read NowLong Ideas - It seems that shares of AVEO Oncology (NASDAQ:AVEO) may have finally found their bottom. The oncology drug-developer bounced off of support at $6 (a triple … Continue Reading
Read NowLong Ideas - Raptor Pharmaceutical (NASDAQ:RPTP) is developing treatments for rare diseases and has a compelling pipeline positioned to take advantage of unmet medical needs. The company has … Continue Reading
Read NowLong Ideas - Shares of ViroPharma (NASDAQ:VPHM) have been pressured in 2012 (falling over 17% as of December 26), as generic competition for one of its drugs has … Continue Reading
Read NowLong Ideas - Happy Holidays from the team at PropThink! Our report on Trius Therapeutics tackled the short thesis, repudiating the focal points of the bear argument. Shares are, … Continue Reading
Read NowLong Ideas - Halozyme Therapeutics (NASDAQ:HALO) announced that it has licensed the use of its technology platform to Pfizer Inc. (NYSE:PFE) to develop Pfizer’s biologics with Halozyme’s Enhanze … Continue Reading
Read Now